Verrica FDA approval of YCANTH for molluscum and Q2 net loss $11M; cash runway to Q1 2025

Verrica Pharmaceuticals Inc.

2023-Q2 EPS reported -$0.40 revenue$219,000

FDA approved YCANTH (cantharidin) on July 21 for molluscum in patients 2+; launch by Sep 2023.
Closed $125M debt facility with OrbiMed; drew $50M, up to $75M additional; cash extends into Q1 2025.
Q2 GAAP net loss $11.0M ($0.24/share) vs $10.2M loss in prior year; non-GAAP loss $9.4M.
Expanding Part 2 enrollment of VP-315 Phase 2 trial for basal cell carcinoma to accelerate development.
Cash and equivalents $55.1M at June 30, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Verrica Pharmaceuticals Inc. reported financial results for six months ended June 30, 2023.

Period: six months ended June 30, 2023
Result: reported results

Exact text from the filing

Verrica Pharmaceuticals Inc. (the " Registrant ") issued a press release announcing its financial results for the quarter and six months ended June 30, 2023.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Verrica Pharmaceuticals Inc. reported second quarter ended June 30, 2023 results: net income net loss on a GAAP basis was $11.0 million, or $0.24 per share, EPS net loss on a GAAP basis was $11.0 million, or $0.24 per share.

Period: second quarter ended June 30, 2023
Net income: net loss on a GAAP basis was $11.0 million, or $0.24 per share
EPS: net loss on a GAAP basis was $11.0 million, or $0.24 per share
Result: reported results

Exact text from the filing

Verrica Pharmaceuticals Inc. (the " Registrant ") issued a press release announcing its financial results for the quarter and six months ended June 30, 2023.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

Verrica Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-205590

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.